ENDMC
MCID: END057
MIFTS: 74

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 56 12 73 36 13 54 6 15
Endometrial Carcinoma 12 29 54 6 15 17 71
Endometrial Neoplasm 12 29 6 17
Malignant Neoplasm of Endometrium 12 71
Carcinoma, Endometrioid 43 71
Endometrioid Carcinoma 12 17
Endometrial Neoplasms 43 71
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 56
Endometrial Carcinoma, Somatic 56
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 56
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Carcinoma Endometrioid 54
Uterine Corpus Cancer 71
Tumor of Endometrium 12
Endometrial Cancers 15
Cancer, Endometrial 39
Endometrial Ca 12
Endmc 73

Characteristics:

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
often seen in cancer predisposition syndromes such as hereditary nonpolyposis colorectal cancer (see )


HPO:

31
endometrial cancer:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:1380 DOID:2871
OMIM 56 608089
KEGG 36 H00026
ICD10 32 C54.1
MedGen 41 C0476089
SNOMED-CT via HPO 68 124975008
UMLS 71 C0007103 C0014170 C0206687 more

Summaries for Endometrial Cancer

KEGG : 36 Endometrial cancer (EC) is the most common gynaecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and colorectal cancer, hereditary nonpolyposis, type 5. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Levonorgestrel and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include tissues lining the uterus, breast and lymph node, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology : 12 A uterine cancer that is located in tissues lining the uterus.

UniProtKB/Swiss-Prot : 73 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

Wikipedia : 74 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

More information from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 715)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 34.7 PTEN MUTYH MSH6 MSH3 MLH3 KRAS
2 colorectal cancer, hereditary nonpolyposis, type 5 33.4 MUTYH MSH6
3 mismatch repair cancer syndrome 33.3 PTEN MSH6 CTNNB1
4 endometrial adenocarcinoma 33.2 PTEN KRAS FGFR2 CTNNB1 CDH1
5 adenocarcinoma 33.1 PTEN MSH6 KRAS FGFR2 CTNNB1 CDH1
6 endometrial hyperplasia 33.0 PTEN MSH6 KRAS CTNNB1
7 carcinosarcoma 32.8 PTEN KRAS CTNNB1 CDH1
8 uterine carcinosarcoma 32.3 PTEN MSH6 KRAS FGFR2 CTNNB1 CDH1
9 colorectal cancer 32.2 UCA1 PTEN NEAT1 MUTYH MSH6 MSH3
10 serous cystadenocarcinoma 32.1 PTEN KRAS CTNNB1
11 cowden syndrome 32.1 PTEN MUTYH MSH6 MLH3 CTNNB1
12 ovarian cancer 32.0 UCA1 PTEN NEAT1 MSH6 MSH3 MIR200C
13 familial adenomatous polyposis 32.0 MUTYH MSH6 MSH3 KRAS CTNNB1 CDH1
14 breast cancer 32.0 UCA1 PTEN NEAT1 MSH6 MSH3 MIR200C
15 uterine corpus cancer 31.9 PTEN MSH6 KRAS CTNNB1 CDH1
16 cervical cancer 31.9 UCA1 PTEN NEAT1 HOTAIR GAS5 CTNNB1
17 female reproductive endometrioid cancer 31.8 PTEN MSH6 KRAS CTNNB1
18 adenoma 31.8 MUTYH MSH6 KRAS CTNNB1 CDH1
19 hereditary breast ovarian cancer syndrome 31.7 PTEN MUTYH MSH6 KRAS
20 endometrioid ovary carcinoma 31.6 PTEN MSH6 KRAS CTNNB1
21 ovarian serous cystadenocarcinoma 31.6 PTEN KRAS CTNNB1 CDH1
22 teratoma 31.6 PTEN KRAS CTNNB1 CDH1
23 prostate cancer 31.5 UCA1 PTEN NEAT1 MSH6 MIR200C KRAS
24 thyroid carcinoma 31.5 PTEN NEAT1 CDH1 CASC2
25 signet ring cell adenocarcinoma 31.5 KRAS CTNNB1 CDH1
26 familial colorectal cancer 31.4 MUTYH CDH1
27 in situ carcinoma 31.3 PTEN CTNNB1 CDH1
28 colorectal adenocarcinoma 31.3 PTEN MSH6 KRAS CTNNB1 CDH1
29 colon adenocarcinoma 31.3 PTEN MSH6 KRAS CTNNB1 CDH1
30 myeloma, multiple 31.3 UCA1 PTEN KRAS HOTAIR GAS5 CTNNB1
31 bladder cancer 31.3 UCA1 PTEN KRAS HOTAIR GAS5 FGFR2
32 bilateral breast cancer 31.3 PTEN MSH6 CDH1
33 ovary adenocarcinoma 31.2 PTEN KRAS CTNNB1 CDH1
34 muir-torre syndrome 31.2 MUTYH MSH6 MSH3 MLH3
35 colorectal adenoma 31.2 MUTYH KRAS CTNNB1 CDH1
36 bladder urothelial carcinoma 31.2 UCA1 PTEN KRAS HOTAIR GAS5 CTNNB1
37 pancreatic adenocarcinoma 31.1 PTEN KRAS FGFR2 CTNNB1 CDH1
38 ovarian cystadenocarcinoma 31.1 PTEN KRAS CTNNB1
39 lung cancer susceptibility 3 31.1 PTEN MIR200C LINC-ROR KRAS HOTAIR GAS5
40 lung squamous cell carcinoma 31.1 PTEN KRAS FGFR2 CTNNB1 CDH1 CCAT1
41 rectum cancer 31.1 MUTYH MSH6 KRAS
42 skin squamous cell carcinoma 31.1 PTEN MSH6 CDH1
43 lung cancer 31.1 UCA1 PTEN NEAT1 MSH3 MIR200C LINC-ROR
44 lymphangioma 31.0 KRAS CTNNB1 CDH1
45 squamous cell carcinoma 31.0 UCA1 PTEN NEAT1 HOTAIR FGFR2 CTNNB1
46 adenoid cystic carcinoma 31.0 PTEN KRAS CTNNB1 CDH1
47 vulvar intraepithelial neoplasia 31.0 CTNNB1 CDH1
48 gallbladder cancer 31.0 UCA1 PTEN LINC-ROR KRAS HOTAIR CTNNB1
49 pancreatic ductal adenocarcinoma 31.0 UCA1 PTEN MIR200C KRAS HOTAIR CTNNB1
50 thyroid gland cancer 31.0 UCA1 PTEN KRAS HOTAIR GAS5 CTNNB1

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Human phenotypes related to Endometrial Cancer:

31
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 31 HP:0012114

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
endometrial cancer

Clinical features from OMIM:

608089

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.55 KRAS
2 Decreased viability GR00055-A-2 9.55 KRAS
3 Decreased viability GR00055-A-3 9.55 KRAS
4 Decreased viability GR00106-A-0 9.55 KRAS
5 Decreased viability GR00221-A-1 9.55 CDH1 KRAS
6 Decreased viability GR00221-A-2 9.55 KRAS
7 Decreased viability GR00249-S 9.55 FGFR2
8 Decreased viability GR00301-A 9.55 CDH1 FGFR2 KRAS MLH3
9 Decreased viability GR00342-S-1 9.55 FGFR2
10 Decreased viability GR00342-S-2 9.55 FGFR2
11 Decreased viability GR00342-S-3 9.55 FGFR2
12 Decreased viability GR00381-A-1 9.55 KRAS
13 Decreased viability GR00402-S-2 9.55 CDH1

MGI Mouse Phenotypes related to Endometrial Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
2
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
3
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
4
Histamine Approved, Investigational Phase 4 51-45-6 774
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Drospirenone Approved Phase 4 67392-87-4 68873
8
Tibolone Approved, Investigational Phase 4 5630-53-5
9
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Ziprasidone Approved Phase 4 146939-27-7 60854
12 Hormone Antagonists Phase 4
13 Hormones Phase 4
14 Estrogens Phase 4
15 Estrogen Receptor Modulators Phase 4
16 Contraceptive Agents Phase 4
17 Contraceptives, Oral Phase 4
18 Contraceptive Agents, Male Phase 4
19
Medroxyprogesterone Phase 4 520-85-4 10631
20 Progestins Phase 4
21 Neurotransmitter Agents Phase 4
22
Histamine Phosphate Phase 4 51-74-1 65513
23 Estradiol 17 beta-cypionate Phase 4
24 Estradiol 3-benzoate Phase 4
25 Antihypertensive Agents Phase 4
26 Adrenergic Agents Phase 4
27 Dopamine Agents Phase 4
28 Dopamine agonists Phase 4
29 Dopamine Antagonists Phase 4
30 Antidepressive Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Serotonin 5-HT1 Receptor Agonists Phase 4
33 Serotonin Receptor Agonists Phase 4
34 Antipsychotic Agents Phase 4
35 Androgen Antagonists Phase 4
36 Anabolic Agents Phase 4
37 Androgens Phase 4
38 Fluorodeoxyglucose F18 Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
40
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
41
Epirubicin Approved Phase 3 56420-45-2 41867
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Ifosfamide Approved Phase 3 3778-73-2 3690
44
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
45
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
46
Promethazine Approved, Investigational Phase 3 60-87-7 4927
47
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
48
Famotidine Approved Phase 3 76824-35-6 3325
49
Cetirizine Approved Phase 3 83881-51-0 2678
50
Olaparib Approved Phase 3 763113-22-0 23725625

Interventional clinical trials:

(show top 50) (show all 966)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study. Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer Completed NCT00190697 Phase 4 arzoxifene
4 Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? Completed NCT03752606 Phase 4
5 Comparative Effects of Drospirenone and Tibolone on the Postmenopausal Endometrium Completed NCT02384408 Phase 4
6 A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Completed NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
7 Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
8 Effects of Tibolone Treatment on the Endometrium Completed NCT00294463 Phase 4 Tibolone;Estradiol;Estradiol + Medroxy Progesterone Acetate
9 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
10 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study. Recruiting NCT03349463 Phase 4 Fluciclovine F18
11 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET Terminated NCT03423082 Phase 4 18F fluciclovine
12 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
13 Role Of Uterine Manipulator in Hysterectomy for Early Stage Endometrial Cancer Unknown status NCT02762214 Phase 3
14 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
15 Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome Unknown status NCT03135301 Phase 3 letrozole plus metformin;letrozole
16 A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy. Unknown status NCT01414517 Phase 3
17 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
18 The HOT Study: Hormone Replacement Therapy Opposed by Low Dose Tamoxifen. A Phase III Trial of Breast Cancer Prevention With Low Dose Tamoxifen in HRT Users. Unknown status NCT01579734 Phase 3 Tamoxifen;Placebo
19 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
20 Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome Unknown status NCT02255578 Phase 3 clomiphene citrate treatment
21 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
22 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
23 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
24 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
25 Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer. Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
26 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
27 A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
28 PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy Completed NCT00376844 Phase 3
29 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
30 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
31 LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial Completed NCT00096408 Phase 3
32 A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND) Completed NCT00003267 Phase 3
33 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
34 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
35 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
36 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
37 A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial Completed NCT01470677 Phase 3 Tachosil fibrin patch
38 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
39 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
40 A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III Completed NCT00002706 Phase 3
41 Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms Completed NCT01464697 Phase 3 Oral micronized progesterone;placebo
42 Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits Completed NCT00490087 Phase 3
43 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream USP, 0.01% (Teva Pharmaceuticals, USA) to Estrace® Estradiol Vaginal Cream, USP, 0.01% (Warner Chilcott) in the Treatment of Atrophic Vaginitis Completed NCT03294538 Phase 3 Generic Estradiol Vaginal Cream USP, 0.01%;Estrace® Vaginal Cream USP, 0.01%;Vehicle Vaginal Cream
44 Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Completed NCT03241888 Phase 2, Phase 3 Megestrol Acetate
45 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
46 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
47 A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer Completed NCT00002967 Phase 3 cyclophosphamide;doxorubicin hydrochloride;octreotide pamoate;tamoxifen citrate
48 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
49 Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy Completed NCT00426257 Phase 3
50 Women's Health Initiative (WHI) Completed NCT00000611 Phase 3 hormone replacement therapy;estrogens;progestins;estrogen replacement therapy;calcium;vitamin D

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carboplatin
Cyclophosphamide
Leuprolide
Leuprolide Acetate
Medroxyprogesterone
medroxyprogesterone acetate
Megestrol
Megestrol Acetate

Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 29 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 29

Anatomical Context for Endometrial Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

19
Tissues Lining The Uterus

MalaCards organs/tissues related to Endometrial Cancer:

40
Breast, Lymph Node, Uterus, Ovary, Testes, Cervix, Lung

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 22510)
# Title Authors PMID Year
1
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. 6 56 54 61
17525745 2007
2
Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. 61 56 6
17956577 2007
3
Drug-sensitive FGFR2 mutations in endometrial carcinoma. 54 56 61
18552176 2008
4
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. 61 54 56
10072435 1999
5
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. 61 54 6
8782829 1996
6
The mutational landscape of normal human endometrial epithelium. 56 61
32350471 2020
7
Endometrial cancer: a review and current management strategies: part I. 6 61
24905773 2014
8
Integrated genomic characterization of endometrial carcinoma. 56 61
23636398 2013
9
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. 56 61
23104009 2012
10
Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer. 56 61
12872259 2003
11
Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. 6 61
9740666 1998
12
Deletion mapping on chromosome 10q25-q26 in human endometrial cancer. 6 61
8980400 1996
13
Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. 6
27476653 2016
14
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. 6
24493721 2014
15
First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. 6
21815886 2011
16
MLH3 and EXO1 alterations in familial colorectal cancer patients not fulfilling Amsterdam criteria. 6
17656264 2007
17
Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene. 6
16440883 2005
18
Beare-Stevenson syndrome: Two South American patients with FGFR2 analysis. 6
12900900 2003
19
The role of hMLH3 in familial colorectal cancer. 6
12702580 2003
20
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. 6
12588804 2003
21
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. 6
12606733 2003
22
Abnormal spliceform expression associated with splice acceptor mutations in exon IIIc of FGFR2. 6
12124745 2002
23
Mutation in the FGFR2 gene in a Taiwanese patient with Beare-Stevenson cutis gyrata syndrome. 6
12000365 2002
24
Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. 6
11818965 2002
25
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. 6
11390973 2001
26
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. 56
11418155 2001
27
Presence of the Apert canonical S252W FGFR2 mutation in a patient without severe syndactyly. 6
9719378 1998
28
A common mitochondrial DNA variant is associated with insulin resistance in adult life. 56
9498630 1998
29
PTEN1 is frequently mutated in primary endometrial carcinomas. 6
9326929 1997
30
Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. 6
8696350 1996
31
Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome. 6
8651276 1996
32
Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. 6
7728760 1995
33
Mutations of the E-cadherin gene in human gynecologic cancers. 6
8075649 1994
34
Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. 54 61
19960433 2010
35
Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. 61 54
20087603 2010
36
Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis. 61 54
19446313 2010
37
IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. 61 54
20472848 2010
38
5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1. 54 61
19306077 2010
39
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. 61 54
20178884 2010
40
Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. 61 54
20053928 2010
41
Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). 61 54
20304627 2010
42
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. 54 61
20153885 2010
43
Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. 54 61
20062086 2010
44
The universal overexpression of a cancer testis antigen hiwi is associated with cancer angiogenesis. 54 61
20204292 2010
45
FGFR2 mutations are rare across histologic subtypes of ovarian cancer. 61 54
20106510 2010
46
Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. 61 54
20492382 2010
47
High density of peritumoral lymphatic vessels is a potential prognostic marker of endometrial carcinoma: a clinical immunohistochemical method study. 54 61
20374665 2010
48
Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients. 54 61
19756737 2010
49
p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. 61 54
20006376 2010
50
Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. 61 54
20179297 2010

Variations for Endometrial Cancer

ClinVar genetic disease variations for Endometrial Cancer:

6 (show top 50) (show all 90) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.1012del (p.Ser338fs)deletion Pathogenic 562182 rs1564568660 10:89720858-89720858 10:87961101-87961101
2 KRAS NM_033360.4(KRAS):c.40G>A (p.Val14Ile)SNV Pathogenic 12589 rs104894365 12:25398279-25398279 12:25245345-25245345
3 FGFR2 NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp)SNV Pathogenic 13272 rs79184941 10:123279677-123279677 10:121520163-121520163
4 FGFR2 NM_000141.5(FGFR2):c.1124A>G (p.Tyr375Cys)SNV Pathogenic 13277 rs121913478 10:123274794-123274794 10:121515280-121515280
5 MLH3 NM_014381.3(MLH3):c.885del (p.His296fs)deletion Pathogenic 5563 rs1431264077 14:75515474-75515474 14:75048771-75048771
6 MSH3 NM_002439.5(MSH3):c.1148del (p.Lys383fs)deletion Pathogenic 8738 rs587776701 5:79970915-79970915 5:80675096-80675096
7 MSH6 NM_000179.2(MSH6):c.2731C>T (p.Arg911Ter)SNV Pathogenic 89312 rs63751017 2:48027853-48027853 2:47800714-47800714
8 MSH6 NM_000179.2(MSH6):c.3103C>T (p.Arg1035Ter)SNV Pathogenic 89338 rs63749999 2:48028225-48028225 2:47801086-47801086
9 MSH6 NM_000179.2(MSH6):c.3202C>T (p.Arg1068Ter)SNV Pathogenic 89352 rs63749843 2:48030588-48030588 2:47803449-47803449
10 CDH1 NM_004360.5(CDH1):c.220C>T (p.Arg74Ter)SNV Pathogenic 239891 rs876658932 16:68835629-68835629 16:68801726-68801726
11 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
12 CDH1 NM_004360.5(CDH1):c.1147C>T (p.Gln383Ter)SNV Pathogenic 142888 rs587782798 16:68847225-68847225 16:68813322-68813322
13 MSH6 NM_000179.3(MSH6):c.10C>T (p.Gln4Ter)SNV Pathogenic/Likely pathogenic 183723 rs786201042 2:48010382-48010382 2:47783243-47783243
14 KRAS NM_033360.4(KRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic/Likely pathogenic 12578 rs121913530 12:25398285-25398285 12:25245351-25245351
15 PTEN NM_000314.7(PTEN):c.253+1G>ASNV Pathogenic/Likely pathogenic 7820 rs587776667 10:89690847-89690847 10:87931090-87931090
16 FGFR2 NM_000141.5(FGFR2):c.1115C>G (p.Ser372Cys)SNV Pathogenic/Likely pathogenic 13278 rs121913477 10:123274803-123274803 10:121515289-121515289
17 CTNNB1 NM_001904.4(CTNNB1):c.98C>A (p.Ser33Tyr)SNV Pathogenic/Likely pathogenic 17577 rs121913400 3:41266101-41266101 3:41224610-41224610
18 MUTYH NM_001048174.2(MUTYH):c.452A>G (p.Tyr151Cys)SNV Pathogenic/Likely pathogenic 5293 rs34612342 1:45798475-45798475 1:45332803-45332803
19 MUTYH NM_001048174.2(MUTYH):c.1103G>A (p.Gly368Asp)SNV Pathogenic/Likely pathogenic 5294 rs36053993 1:45797228-45797228 1:45331556-45331556
20 subset of 54 genes: SPAST inv(2)(p21p23.2)inversion Likely pathogenic 547174 2:29447680-42554394
21 PIK3CA NM_006218.4(PIK3CA):c.3074C>G (p.Thr1025Ser)SNV Likely pathogenic 495324 rs1553826166 3:178952019-178952019 3:179234231-179234231
22 FGFR3 , LOC116158483 , TACC3 NC_000004.11:g.1737488_1808653dupduplication Likely pathogenic 495323 4:1737488-1808653 4:1735761-1806926
23 FGFR2 NM_000141.5(FGFR2):c.1642A>C (p.Ile548Leu)SNV Likely pathogenic 376433 rs1057519901 10:123258039-123258039 10:121498525-121498525
24 FGFR2 NM_000141.5(FGFR2):c.1972A>G (p.Lys658Glu)SNV Likely pathogenic 376725 rs1057520027 10:123247519-123247519 10:121488005-121488005
25 FGFR2 NM_000141.5(FGFR2):c.1121A>G (p.Asp374Gly)SNV Likely pathogenic 376726 rs1057520028 10:123274797-123274797 10:121515283-121515283
26 FGFR2 NM_000141.5(FGFR2):c.1974A>T (p.Lys658Asn)SNV Likely pathogenic 376727 rs1057520029 10:123247517-123247517 10:121488003-121488003
27 CTNNB1 NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn)SNV Likely pathogenic 376228 rs28931588 3:41266097-41266097 3:41224606-41224606
28 CTNNB1 NM_001904.4(CTNNB1):c.95A>T (p.Asp32Val)SNV Likely pathogenic 376230 rs121913396 3:41266098-41266098 3:41224607-41224607
29 FGFR2 NM_000141.5(FGFR2):c.1914T>A (p.Asn638Lys)SNV Likely pathogenic 376315 rs1057519854 10:123247577-123247577 10:121488063-121488063
30 FGFR2 NM_000141.5(FGFR2):c.1141T>C (p.Tyr381His)SNV Likely pathogenic 376316 rs387906678 10:123274777-123274777 10:121515263-121515263
31 FGFR2 NM_000141.5(FGFR2):c.929A>G (p.Lys310Arg)SNV Likely pathogenic 376317 rs121913475 10:123279503-123279503 10:121519989-121519989
32 MSH6 NM_000179.2(MSH6):c.3801+1G>TSNV Likely pathogenic 234228 rs876660943 2:48033498-48033498 2:47806359-47806359
33 MSH6 NM_000179.2(MSH6):c.187T>C (p.Ser63Pro)SNV Conflicting interpretations of pathogenicity 220796 rs763702846 2:48010559-48010559 2:47783420-47783420
34 MLH3 NM_001040108.1(MLH3):c.2911G>A (p.Val971Ile)SNV Conflicting interpretations of pathogenicity 410896 rs41555714 14:75513448-75513448 14:75046745-75046745
35 MSH6 NM_000179.3(MSH6):c.2561A>T (p.Lys854Met)SNV Conflicting interpretations of pathogenicity 89289 rs34374438 2:48027683-48027683 2:47800544-47800544
36 MSH6 NM_000179.2(MSH6):c.1063G>A (p.Gly355Ser)SNV Conflicting interpretations of pathogenicity 134851 rs587778531 2:48026185-48026185 2:47799046-47799046
37 MSH6 NM_000179.3(MSH6):c.3259C>T (p.Pro1087Ser)SNV Conflicting interpretations of pathogenicity 89360 rs63750998 2:48030645-48030645 2:47803506-47803506
38 MSH6 NM_000179.3(MSH6):c.3260C>G (p.Pro1087Arg)SNV Conflicting interpretations of pathogenicity 89362 rs63750753 2:48030646-48030646 2:47803507-47803507
39 MSH6 NM_000179.2(MSH6):c.3605T>C (p.Met1202Thr)SNV Conflicting interpretations of pathogenicity 89424 rs587779273 2:48032805-48032805 2:47805666-47805666
40 MSH6 NM_000179.3(MSH6):c.73G>T (p.Ala25Ser)SNV Conflicting interpretations of pathogenicity 89562 rs267608026 2:48010445-48010445 2:47783306-47783306
41 MSH6 NM_000179.2(MSH6):c.3788G>A (p.Arg1263His)SNV Conflicting interpretations of pathogenicity 127593 rs147852216 2:48033484-48033484 2:47806345-47806345
42 PTEN NM_000314.8(PTEN):c.882T>G (p.Ser294Arg)SNV Uncertain significance 127693 rs143335584 10:89720731-89720731 10:87960974-87960974
43 PTEN NM_000314.8(PTEN):c.892C>G (p.Gln298Glu)SNV Uncertain significance 127695 rs371387815 10:89720741-89720741 10:87960984-87960984
44 MSH6 NM_000179.3(MSH6):c.2419G>A (p.Glu807Lys)SNV Uncertain significance 127570 rs587779923 2:48027541-48027541 2:47800402-47800402
45 MSH6 NM_000179.2(MSH6):c.383G>T (p.Arg128Leu)SNV Uncertain significance 89473 rs63750143 2:48018188-48018188 2:47791049-47791049
46 MSH6 NM_000179.3(MSH6):c.3299C>T (p.Thr1100Met)SNV Uncertain significance 89369 rs63750442 2:48030685-48030685 2:47803546-47803546
47 CDH1 NM_004360.5(CDH1):c.2474C>T (p.Pro825Leu)SNV Uncertain significance 140841 rs587781312 16:68867227-68867227 16:68833324-68833324
48 MSH6 NM_000179.3(MSH6):c.1814C>G (p.Thr605Ser)SNV Uncertain significance 141265 rs587781616 2:48026936-48026936 2:47799797-47799797
49 MSH6 NM_000179.2(MSH6):c.3244C>T (p.Pro1082Ser)SNV Uncertain significance 141299 rs186240214 2:48030630-48030630 2:47803491-47803491
50 MSH6 NM_000179.3(MSH6):c.3557G>A (p.Gly1186Asp)SNV Uncertain significance 141364 rs587781690 2:48032757-48032757 2:47805618-47805618

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

73
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 47039)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88264503 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 24
2 COSM88264271 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 24
3 COSM88264495 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 24
4 COSM149332944 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 24
5 COSM149265473 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8512G>A p.V2838I 16:72794170-72794170 24
6 COSM149320029 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 24
7 COSM149276742 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1753G>A p.G585S 16:72958393-72958393 24
8 COSM149319798 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 24
9 COSM149259590 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1936G>A p.D646N 16:72958210-72958210 24
10 COSM149286811 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 24
11 COSM149314151 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3709C>T p.R1237W 16:72811732-72811732 24
12 COSM149261368 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4342C>A p.L1448I 16:72798340-72798340 24
13 COSM149284453 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4653G>T p.K1551N 16:72798029-72798029 24
14 COSM149265910 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 24
15 COSM149292038 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8633C>T p.A2878V 16:72794049-72794049 24
16 COSM149293431 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 24
17 COSM149281700 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8617G>A p.E2873K 16:72794065-72794065 24
18 COSM149322559 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2861C>T p.T954M 16:72950824-72950824 24
19 COSM149264593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.629G>A p.G210D 16:72959517-72959517 24
20 COSM149261344 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 24
21 COSM149280950 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 24
22 COSM149296225 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 24
23 COSM149293444 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6906G>T p.E2302D 16:72795776-72795776 24
24 COSM149298176 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2119G>A p.G707R 16:72958027-72958027 24
25 COSM149289617 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6965G>A p.R2322Q 16:72795717-72795717 24
26 COSM149293449 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.710G>A p.R237Q 16:72959436-72959436 24
27 COSM149293438 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6935G>A p.R2312Q 16:72795747-72795747 24
28 COSM149297062 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 24
29 COSM149313577 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 24
30 COSM149261333 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 24
31 COSM149320045 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2459G>A p.R820H 16:72957687-72957687 24
32 COSM149321526 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1031A>C p.N344T 16:72959115-72959115 24
33 COSM149290487 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2919G>T p.E973D 16:72950766-72950766 24
34 COSM149320020 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 24
35 COSM149278018 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 24
36 COSM149270196 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3925C>T p.R1309* 16:72800069-72800069 24
37 COSM149302952 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 24
38 COSM149323327 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6881G>A p.R2294Q 16:72795801-72795801 24
39 COSM149281672 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6751G>A p.D2251N 16:72795931-72795931 24
40 COSM149272466 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7882G>A p.E2628K 16:72794800-72794800 24
41 COSM149283769 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 24
42 COSM149325401 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 24
43 COSM149308919 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4315C>T p.R1439* 16:72798367-72798367 24
44 COSM149262204 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 24
45 COSM149272477 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 24
46 COSM149282136 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8029G>A p.E2677K 16:72794653-72794653 24
47 COSM149302940 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 24
48 COSM149281678 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5650G>T p.E1884* 16:72797032-72797032 24
49 COSM149290480 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4072T>G p.S1358A 16:72798610-72798610 24
50 COSM149265665 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 24

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Endometrial cancer hsa05213

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 PTEN MSH6 MSH3 KRAS FGFR2 CTNNB1
2
Show member pathways
12.52 PTEN KRAS FGFR2 CTNNB1 CDH1
3
Show member pathways
12.4 PTEN MSH6 KRAS FGFR2 CDH1
4
Show member pathways
12.23 PTEN KRAS FGFR2 CTNNB1 CDH1
5 11.94 MSH6 MSH3 KRAS CTNNB1 CDH1
6 11.89 PTEN MSH6 MSH3 KRAS FGFR2 CTNNB1
7 11.75 PTEN KRAS CTNNB1
8 11.69 FGFR2 CTNNB1 CDH1
9
Show member pathways
11.65 MSH6 MSH3 MLH3
10 11.54 PTEN MSH6 KRAS CTNNB1 CDH1
11 11.45 PTEN KRAS FGFR2
12 10.59 CTNNB1 CDH1
13 10.41 UCA1 LINC-ROR HOTAIR

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 9.16 CTNNB1 CDH1
2 MutSalpha complex GO:0032301 8.96 MSH6 MSH3
3 mismatch repair complex GO:0032300 8.8 MSH6 MSH3 MLH3

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell differentiation GO:0045603 9.55 MIR200C CTNNB1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 KRAS CTNNB1
3 negative regulation of DNA recombination GO:0045910 9.52 MSH6 MSH3
4 regulation of osteoblast differentiation GO:0045667 9.51 FGFR2 CTNNB1
5 regulation of synaptic transmission, GABAergic GO:0032228 9.49 PTEN KRAS
6 morphogenesis of embryonic epithelium GO:0016331 9.48 FGFR2 CTNNB1
7 lung-associated mesenchyme development GO:0060484 9.46 FGFR2 CTNNB1
8 entry of bacterium into host cell GO:0035635 9.43 CTNNB1 CDH1
9 positive regulation of helicase activity GO:0051096 9.4 MSH6 MSH3
10 cellular response to indole-3-methanol GO:0071681 9.37 CTNNB1 CDH1
11 maintenance of DNA repeat elements GO:0043570 9.32 MSH6 MSH3
12 somatic recombination of immunoglobulin gene segments GO:0016447 9.26 MSH6 MSH3
13 mesenchymal cell proliferation involved in lung development GO:0060916 9.16 FGFR2 CTNNB1
14 meiotic mismatch repair GO:0000710 8.96 MSH6 MSH3
15 mismatch repair GO:0006298 8.92 MUTYH MSH6 MSH3 MLH3

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex binding GO:0032405 9.32 MUTYH MSH6
2 guanine/thymine mispair binding GO:0032137 9.26 MSH6 MSH3
3 single guanine insertion binding GO:0032142 9.16 MSH6 MSH3
4 mismatched DNA binding GO:0030983 9.13 MSH6 MSH3 MLH3
5 oxidized purine DNA binding GO:0032357 8.8 MUTYH MSH6 MSH3

Sources for Endometrial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....